Welcome to our dedicated page for Sensus Healthcare SEC filings (Ticker: SRTS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Sensus Healthcare, Inc. filings document the financial reporting, governance and material-event disclosures of a Nasdaq-listed medical-device company focused on superficial radiotherapy systems for skin conditions. Recent Form 8-K filings furnish quarterly and annual results, non-GAAP reconciliations, business highlights, reimbursement-related disclosures, cash and debt information, and operating updates tied to SRT and IG-SRT systems.
The company’s proxy and governance filings cover annual-meeting matters, director elections, advisory executive-compensation votes, auditor ratification, board composition and independent-director appointments. Other current reports address changes in the independent registered public accounting firm, internal-control disclosures, financial-statement exhibits and related corporate-governance matters.
Sensus Healthcare, Inc. entered into a new revolving credit facility with City National Bank of Florida, providing up to $15,000,000 in borrowings. The loan bears interest at the Secured Overnight Financing Rate plus 3% per annum and matures on June 5, 2027, unless extended by mutual agreement.
The facility is secured by $2,230,000 in cash collateral and a security interest in all of the company’s assets. The agreement restricts asset sales outside the ordinary course, additional indebtedness, new liens, and removal of the CEO, President, or CFO without the bank’s consent. Sensus must maintain a minimum debt service coverage ratio of 1.50, with customary default provisions that allow the bank to accelerate the loan and exercise remedies against collateral.
Sensus Healthcare, Inc. reported the results of its Annual Meeting of Stockholders held on May 29, 2026. Stockholders elected incumbent Class II directors Eric Sachetta and Michael J. Sardano to three-year terms expiring in 2029.
For the director elections, Sachetta received 5,532,247 votes for, 516,567 against, 270,440 abstentions, and 5,000,719 broker non-votes. Sardano received 4,702,852 votes for, 1,346,063 against, 270,339 abstentions, and 5,000,719 broker non-votes.
Stockholders also approved, on a non-binding advisory basis, the 2025 executive compensation program, with 4,740,572 votes for, 856,128 against, 722,554 abstentions, and 5,000,719 broker non-votes. In addition, stockholders ratified the appointment of Carr, Riggs & Ingram, LLC as independent registered public accountant for the year ending December 31, 2026, with 10,738,792 votes for, 148,466 against, and 432,715 abstentions.
Sensus Healthcare director Eric Sachetta reported an open-market purchase of company stock. On May 12, 2026, he bought 1,500 shares of Sensus Healthcare, Inc. common stock at $3.335 per share.
Following this transaction, he directly holds 143,613 common shares and also reports indirect ownership of 2,093 shares held by his spouse.
Sensus Healthcare reported first quarter 2026 revenue of $3.4 million, down from $8.3 million a year earlier, mainly because its historically largest customer did not purchase in the period and more systems were placed under rental and Fair Deal Agreement structures.
Gross margin fell to 29.2% from 52.2% due to product mix, including more international shipments and costs tied to new placements recognized over time. Net loss was $2.6 million, or $0.16 per share, similar to the prior-year quarter, while Adjusted EBITDA declined to negative $4.2 million from negative $2.5 million.
The company ended March 31, 2026 with $18.3 million in cash and cash equivalents and no debt. Management highlighted newly effective dedicated CPT codes for superficial radiotherapy, growing interest from a more diversified customer base, and initiatives to expand higher-margin recurring revenue as it works toward profitability.
Sensus Healthcare is asking stockholders to vote at its 2026 Annual Meeting on May 29, 2026 in Boca Raton. Holders of 16,462,059 common shares as of April 10, 2026 may vote to elect two Class II directors through 2029, approve an advisory say‑on‑pay resolution, and ratify Carr, Riggs & Ingram, LLC as auditor for 2026.
The proxy details board structure, committee memberships and director independence, as well as 2025 pay for key executives, including a $600,000 base salary and total compensation of $1,417,860 for CEO Joseph C. Sardano and $1,213,917 for President and General Counsel Michael Sardano. It also describes employment agreements, change‑in‑control severance and a clawback policy tied to accounting restatements, plus prior auditor changes and 2025 audit fees.
Sensus Healthcare director Eric Sachetta filed an amended Form 4 to correct previously reported holdings. The filing clarifies that his spouse holds 2,093 shares of Sensus Healthcare common stock indirectly attributed to him. Earlier Forms 4 had inadvertently omitted these indirectly owned shares, and this amendment updates the reported ownership without reflecting any new buy or sell transaction.
Sensus Healthcare, Inc. chief financial officer Javier Rampolla reported a routine share adjustment linked to equity compensation. On July 21, 2022, 3,935 shares of common stock were withheld at $10.51 per share to cover his tax obligation from vested restricted stock. After this withholding, he beneficially owned 48,114 shares of common stock directly. The amended filing also corrects an earlier Form 4 that had overstated his holdings by 742 shares, revising the previously reported 48,856 shares to the accurate 48,114 shares as of that date.
Sensus Healthcare, Inc. executive Magdalena Martinez, the chief operating officer, filed an amended Form 3 to correct her reported share ownership. The original filing stated she held 18,000 shares of common stock, including restricted stock, but this amendment clarifies she actually held 12,754 shares as of January 3, 2023.
Sensus Healthcare, Inc. reported that Chief Operating Officer Magdalena Martinez had 741 shares of common stock withheld at $2.66 per share to satisfy withholding taxes arising from the vesting of restricted stock on December 19, 2023. After this tax-withholding disposition, she held 12,013 shares of common stock, including 7,500 shares of restricted stock, as of that date. The amended filing corrects a prior Form 4 that had understated her holdings as 9,759 shares.